FHND-9041 is under clinical development by Jiangsu Zhengda Fenghai Pharmaceutical and currently in Phase III for Non-Small Cell Lung Cancer. According to GlobalData, Phase III drugs for Non-Small Cell Lung Cancer have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how FHND-9041’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FHND-9041 is under development for the treatment of T790 mutation (T790M) positive non-small cell lung cancer (second line). It is administered orally in the form of capsules. It acts by targeting T790 mutated epidermal growth factor receptor (EGFR T790M).
For a complete picture of FHND-9041’s drug-specific PTSR and LoA scores, buy the report here.